HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Risk–benefit ratio requires ‘highly individualized’ plan for extended aromatase inhibitor therapy
-
- Palliative care in oncology: Dedication always, specialists often Arif Kamal, MD, MHS, FACP, FAAHPM, FASCO
- BERG initiates trial of BPM 31510-IV for glioblastoma
- Boston Biomedical initiates phase 3 study of napabucasin for pancreatic cancer
- Cleveland Clinic set to open ‘revolutionary’ cancer center
- Olaparib extends PFS in BRCA–mutated metastatic breast cancer
- Roswell Park Cancer Institute launches trial to test Cuban lung cancer vaccine
- Single infusion of anti-CD19 CAR T-cells confers high response rate in aggressive non-Hodgkin lymphoma
- Society leaders: 2017 likely to be time of ‘unprecedented’ advances in hematology, oncology
-
- Strict clinical trial eligibility criteria exclude patients most likely to benefit from cancer treatment
- Tivantinib fails to improve OS in hepatocellular carcinoma
- The cost of living: Financial constraints put benefits of revolutionary treatments at risk John Sweetenham, MD, FRCP, FACP
- FDA grants breakthrough therapy designation to Toca 511 and Toca FC for high-grade glioma
- FDA grants priority review to Zykadia for ALK–positive metastatic NSCLC
- PET/CT for esophageal carcinoma staging detects clinically unsuspected synchronous malignancy Munir Ghesani, MD, FACNM; Ana M. Franceschi, MD
- Abbreviated high-dose interferon induction fails to prolong RFS in melanoma
- Antiandrogen therapy may improve recurrent prostate cancer survival
-
- ASCO guideline recommends early integration of palliative, standard oncology care
- Chemotherapy-free regimen shows favorable long-term safety, efficacy in Waldenström macroglobulinemia
- Decitabine especially effective in TP53–mutated AML, myelodysplastic syndrome
- Delayed adjuvant chemotherapy does not increase NSCLC mortality
- E-cigarettes proven safer than traditional cigarettes
- Endocrine disorders prevalent among childhood brain tumor survivors
- Fulvestrant prolongs PFS for women with hormone receptor– positive advanced breast cancer
- Genetic testing could help define VTE risk in patients with breast cancer
-
- Hospice improves end-of-life care for patients with lung, colorectal cancers
- Intentional weight loss lowers risk for endometrial cancer in postmenopausal women
- Toxicity rates high after cetuximab therapy for anal carcinoma
- Whole-brain radiotherapy provides little benefit for NSCLC with brain metastases
- Diverse gut microbiome may improve response to immunotherapy for melanoma
- Value of biomarkers in colorectal cancer depends on tumor location
- Does the efficacy of bisphosphonates support the use of extended aromatase inhibitor therapy in women at risk for bone fractures?